A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato. [electronic resource]
Producer: 20150623Description: 1490-9 p. digitalISSN:- 1556-679X
- Adjuvants, Immunologic -- administration & dosage
- Adolescent
- Adult
- Aged
- Alum Compounds -- administration & dosage
- Antibodies, Bacterial -- blood
- Antigens, Surface -- administration & dosage
- Bacterial Outer Membrane Proteins -- administration & dosage
- Bacterial Vaccines -- administration & dosage
- Borrelia burgdorferi Group -- immunology
- Double-Blind Method
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Lipoproteins -- administration & dosage
- Lyme Disease -- immunology
- Male
- Middle Aged
- Vaccination -- adverse effects
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.